Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Rev. clín. esp. (Ed. impr.) ; 223(3): 154-164, mar. 2023.
Article in Spanish | IBECS | ID: ibc-217178

ABSTRACT

Antecedentes y objetivo Es bien sabido que las terapias biológicas reducen las exacerbaciones y mejoran el tratamiento del asma grave no controlada. La administración domiciliaria de biológicos ha aumentado durante la pandemia de COVID-19, pero aún no se han identificado las características de los pacientes con asma grave no controlada que pueden beneficiarse de la administración domiciliaria de terapia biológica. Materiales y métodos Este proyecto se basa en la metodología Delphi, diseñada para alcanzar un consenso entre expertos a través de un comité científico multidisciplinar que aborda las siguientes cuestiones: características clínicas, adherencia al tratamiento, capacidad de administración del paciente o cuidador, autocuidado del paciente, relación con el profesional sanitario, preferencias del paciente y acceso al hospital. Resultados Ciento treinta y un profesionales sanitarios (neumólogos, alergólogos, enfermeros y farmacéuticos hospitalarios) cumplimentaron las dos rondas de consenso del cuestionario Delphi. Se identificaron 14 ítems como características prioritarias, siendo los cinco primeros: 1. El paciente sigue las indicaciones/recomendaciones del equipo sanitario para controlar su enfermedad. 2. El paciente es capaz de detectar cualquier deterioro de su enfermedad y de identificar los factores desencadenantes de las exacerbaciones. 3. El paciente recibe tratamiento biológico y tiene una enfermedad estable sin riesgo vital. 4. El paciente se responsabiliza de su autocuidado y 5. el paciente tiene obligaciones laborales/educativas que le impiden acudir al hospital con regularidad (AU)


Background and objective Biologic therapies are known to reduce exacerbations and improve severe uncontrolled asthma management. The at-home administration of biologics has increased during the COVID-19 pandemic, but the characteristics of severe uncontrolled asthma patients who may benefit from at-home administration of biologic therapy have yet to be identified. Materials and methods This project is based on the Delphi method, designed to reach an expert consensus through a multidisciplinary scientific committee addressing the following questions: clinical characteristics, treatment adherence, patient or caregiver administration ability, patient self-care, relationship with the healthcare professional, patient preference, and access to the hospital. Results One hundred and thirty-one healthcare professionals (pulmonologists, allergists, nurses, and hospital pharmacists) completed two Delphi consensus questionnaires. Fourteen items were identified as priority characteristics, the first five being: 1. The patient follows the healthcare team's indications/recommendations to control their disease, 2. The patient is capable of detecting any deterioration in their disease and of identifying exacerbation triggers, 3. The patient receives biologic therapy and has stable disease with no vital risk, 4. The patient takes responsibility for their self-care, 5. The patient has occupational/educational obligations that prevent them from going to the hospital regularly. Conclusions Disease stability and control plus the ability to identify exacerbation triggers are the most important characteristics when opting for at-home administration for a patient with severe uncontrolled asthma on biologic therapy. These recommendations could be applicable in clinical practice (AU)


Subject(s)
Humans , Asthma/diagnosis , Asthma/drug therapy , Biological Products/therapeutic use , Coronavirus Infections , Pandemics , Severity of Illness Index , Delphi Technique , Consensus
2.
Rev Clin Esp (Barc) ; 223(3): 154-164, 2023 03.
Article in English | MEDLINE | ID: mdl-36549642

ABSTRACT

BACKGROUND AND OBJECTIVE: Biologic therapies are known to reduce exacerbations and improve severe uncontrolled asthma management. The at-home administration of biologics has increased during the COVID-19 pandemic, but the characteristics of severe uncontrolled asthma patients who may benefit from at-home administration of biologic therapy have yet to be identified. MATERIALS AND METHODS: This project is based on the Delphi method, designed to reach an expert consensus through a multidisciplinary scientific committee addressing the following questions: clinical characteristics, treatment adherence, patient or caregiver administration ability, patient self-care, relationship with the healthcare professional, patient preference, and access to the hospital. RESULTS: One hundred and thirty-one healthcare professionals (pulmonologists, allergists, nurses, and hospital pharmacists) completed two Delphi consensus questionnaires. Fourteen items were identified as priority characteristics, the first five being: 1. The patient follows the healthcare team's indications/recommendations to control their disease, 2. The patient is capable of detecting any deterioration in their disease and of identifying exacerbation triggers, 3. The patient receives biologic therapy and has stable disease with no vital risk, 4. The patient takes responsibility for their self-care, 5. The patient has occupational/educational obligations that prevent them from going to the hospital regularly. CONCLUSION: Disease stability and control plus the ability to identify exacerbation triggers are the most important characteristics when opting for at-home administration for a patient with severe uncontrolled asthma on biologic therapy. These recommendations could be applicable in clinical practice.


Subject(s)
Asthma , Biological Products , COVID-19 , Humans , Consensus , Pandemics , Asthma/diagnosis , Asthma/drug therapy , Biological Products/therapeutic use
3.
Rev. patol. respir ; 13(1): 3-9, ene.-mar. 2010. tab, graf
Article in Spanish | IBECS | ID: ibc-98158

ABSTRACT

Introducción. La desnutrición hospitalaria se ha estimado entre un 25-50% y se ha relacionado con la mortalidad, aumento de días de estancia y reingresos hospitalarios. Objetivo. Valorar la desnutrición en pacientes ingresados en el servicio de neumología mediante herramientas sencillas y fácilmente aplicables. Pacientes y métodos. A los pacientes que ingresaron en el servicio de neumología desde 1 de septiembre del 2008 hasta el 15 de enero del 2009 se les valoró el estado nutricional mediante 2 parámetros bioquímicos, el índice de masa corporal (IMC) y el cuestionario de SNAQ (Short Nutritional Assessment Questionnaire). Las puntuaciones totales y la clasificación nutricional obtenida se compararon con el número de exacerbaciones e ingresos. Resultados. Se han valorado 141 enfermos con una edad media 66,07 (rango, 18-93 años), 78 hombres y 63 mujeres. Los principales diagnósticos fueron EPOC en un 28,6%, neumonía en un 25%, asma en un 10% e infección respiratoria en un 7,9%. El número de agudizaciones en el año previo fue de 1,55 (rango: 0-10) y de ingresos de 1,01 (rango 0-8). Según el IMC, el 11% presentó desnutrición leve, 2,2% moderada y 0,7% grave. El 49,3% de los pacientes mostraron un IMC > 25 kg/m2. Teniendo en cuenta la albúmina, el 24,1% desnutrición leve, 6,4% moderada y 5% grave y, según los linfocitos, el 22, 23,4 y 22%, leve, moderada y grave, respectivamente. Según el cuestionario SNAQ, el 23,3% mostraba desnutrición. La puntuación total de SNAQ se relacionó con el número de exacerbaciones e ingresos previos y sólo el IMC con las agudizaciones. Conclusiones. Un elevado porcentaje de pacientes presentan desnutrición y ello puede ser causa o consecuencia de los ingresos hospitalarios. Mediante métodos sencillos, aplicables en la práctica clínica habitual, podemos valorar el estado nutricional de nuestros enfermos y actuar precozmente (AU)


Abstract. Hospital malnutrition is estimated between 25-50% and it has been associated with mortality, increased days of hospitalization and readmissions. Objective. To assess malnutrition in patients admitted to the Pneumology Department using simple tools and easy to apply. Patients and methods. Patients admitted in the Pneumology Department from the 1st September 2008 until 15 January 2009 were assessed using 2 nutritional biochemical parameters, body mass index (BMI) and the questionnaire SNAQ (Short Nutritional Assessment Questionnaire). The total scores and nutritional classification were compared with the number of exacerbations and income. Results. We evaluated 141 patients with a mean age 66.07 (range 18 - 93 years), 78 men and 63 women. The main diagnoses were COPD in 28.6%, pneumonia 25%, 10% asthma and respiratory infection 7.9%. The number of exacerbations in the previous year was 1.55 (range: 0-10) and revenue of 1.01 (range 0-8). According to BMI, 11% had mild, moderate 2.2% and 0.7% severe. 49.3% of patients showed a BMI > 25 kg/m2.Considering albumin, 24.1% mild, 6.4% and 5% moderate and severe malnutrition according lymphocytes: 22%, 23.4% and 22% respectively mild, moderate and severe according to the questionnaire the SNAQ 23.3% showed malnutrition. SNAQ total score was related to the number of exacerbations, and previous hospitalization and BMI with the exacerbation. Conclusions. A high percentage of patients develop malnutrition and this could be one cause or consequence of hospital admissions. Using simple methods, applicable in routine clinical practice, we can assess the nutritional status of our patients and act earlier (AU)


Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Nutrition Assessment , Nutrition Disorders/epidemiology , Nutritional Status , Hospitalization/statistics & numerical data , Body Weight , Body Mass Index , Serum Albumin/analysis
4.
Rev. patol. respir ; 11(2): 61-66, abr.-jun. 2008. ilus, tab, graf
Article in Spanish | IBECS | ID: ibc-102214

ABSTRACT

Objetivo: Estudio descriptivo en el que se valoran los ciclos de tratamiento antibiótico domiciliario (TAIVD) que se han originado en una Unidad de FQ de adultos de 55 pacientes en un periodo de 5 años. Se analizaron las características de los pacientes, tipo de antibioterapia, acceso venoso utilizado, así como los dispositivos de administración, complicaciones surgidas y resolución de las mismas. Pacientes y métodos: Se incluyeron en el estudio los pacientes con FQ que recibieron TAIVD a lo largo del periodo enero 2002-diciembre 2006. Se recogieron las siguientes variables de los enfermos: edad, sexo, colonización bacteriana dela vía aérea y función pulmonar en fase estable. Resultados: 29 enfermos: 14 varones y 15 mujeres. Recibieron un total de 98 ciclos de antibioterapia intravenosa. La edad media fue de 25,31 (6,83) años. El 62% estaban colonizados por Pseudomonas aeruginosa. Los antibióticos más utilizados fueron ceftazidima y tobramicina. Los pacientes permanecieron una media de 3,62 (4,13) días ingresados en el hospital y 12,27 (4,16) en domicilio. En todos los casos se utilizó la vía periférica, salvo en 3 ciclos en que se usó catéter central de inserción periférica para la administración de los antibióticos. En el 37% de los casos se perdió el acceso venoso y en el 19,2% se produjo flebitis. La canalización de la nueva vía periférica se realizó en el 60,4% por la enfermera de la Unidad de FQ correspondiente, en un 23,25% por el hospital más cercano y en un 12,6% por el Centro de Salud. En 3 casos se presentaron reacciones cutáneas y en 4, alteraciones gastrointestinales secundarias al antibiótico. Conclusiones: La TAIVD es una modalidad terapéutica que, ajustándose a unos criterios de inclusión y exclusión predeterminados, presenta escasas complicaciones y permite reducir el número de estancias hospitalarias. Previsiblemente el uso de la TAIVD se incremente en los próximos años debido a la mayor expectativa de vida de estos enfermos y a que la terapia domiciliaria es la elegida por la población adulta con FQ (AU)


Objectives: A descriptive study of the home intravenous antibiotic treatment (HIVAT) course in CF Units of fifty five patients in period of six years. Different patient features were recorded, antibiotherapy, intravenous access, complications and their resolutions. We accessed the improvement of the pulmonary function, forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) at the end of the treatment. Patients and Methods: For a five years period (January 2002-December 2006) the patients with CF who received HIVAT and fulfilled the previously fixed criteria were included. The next clinic variables were collected: age, sex, bacterial colonization of respiratory tree, pancreatic function and pulmonary function in steady phase. Results: 29 patients, 14 male and 15 female, were given 98 courses of HIAT. Mean age was 25.31 (6.83) years. 62% of the patients were colonized by Pseudomonas aeruginosa. The most frequently used antibiotics were ceftazidime and tobramycin. Courses of treatment lasted a mean of 3,62 (4,13) days inpatient and 12.27 (4.16) at home. The most of the course were used the intravenous cannula, but in three courses used insertion of peripheral central catheter. The intravenous access was replaced, in the 60.4% of the cases, by the nurse of the CF Unit, in the 23,25% in the emergency room of the nearest hospital and in 12,6% in primary care centre. Three occasions skin reactions were reported and four cases gastrointestinal disorders secondary to antibiotic. The parameters of pulmonary function improved significatively after HIVAT. Conclusions: The HIVAT is a therapeutic option that, following predetermined inclusion criteria, has a low complication rate and permit reduction hospitalization. Probably, HIVAT will be an increasing therapeutic option due to the rise of life expectancy and to that the domiciliary therapy is the chosen one by the adult population with CF (AU)


Subject(s)
Humans , Anti-Bacterial Agents/administration & dosage , Cystic Fibrosis/drug therapy , Home Care Services, Hospital-Based , Nursing Care/methods , Injections, Intravenous , Clinical Protocols
SELECTION OF CITATIONS
SEARCH DETAIL
...